Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bicisate** is a lipophilic small-molecule ligand used in the diagnostic radiopharmaceutical product **Neurolite**. After reconstitution and chelation with technetium Tc 99m, technetium Tc 99m bicisate passively diffuses across intact cell membranes and the blood-brain barrier; stereospecific intracellular de-esterification then promotes cerebral retention in proportion to regional cerebral blood flow. It is administered intravenously for SPECT imaging as an adjunct to CT or MRI for localization of stroke in patients with an established stroke diagnosis. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f9adbcd5-1ac1-42d8-b18a-a76c9204014c))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bicisate.